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Introduction
Despite recent progress in therapy, melanoma has remained by far 
the deadliest skin cancer, with a 5-year survival rate of only 15% 
to 20% (1). There is increasing evidence that the aggressiveness 
of the disease is largely due to an intrinsic plasticity of melano-
ma cells, allowing the dynamic and reversible switching from a 
high-proliferative/low-invasive to a low-proliferative/high-inva-
sive state (2–5). This so-called “phenotype switching” has been 
functionally associated with metastasis formation and therapy 
resistance (6–8, 5). Furthermore, phenotype switching has been 
linked to a shift between a transcriptional program governed by 
high expression of the microphthalmia-associated transcription 
factor (MITF), a melanoma lineage-survival oncogene, and a 
transcriptional program associated with high expression of the 
receptor tyrosine kinase AXL, a marker for resistance to various 
targeted therapies (9–12). In contrast to proliferative melanoma 
cells characterized by high MITF expression, MITFlo cells with 
high-invasive properties show a G1 cell cycle arrest (13). Howev-
er, while the distinction between MITFloAXLhi and MITFhiAXLlo 
phenotypes was used to classify melanomas at the bulk tumor 
level (14), single-cell RNA-Seq of human melanoma samples has 
recently led to the identification of a small fraction of double-posi-
tive MITFhiAXLhi cells. It is conceivable that such double-high cells 
simply represent a transition stage between the 2 phenotypes, but 
alternatively, they may also have specific tumorigenic properties 
that are yet to be elucidated (15).
Phenotype switching has also been linked to tumor progres-
sion in several epithelial tumors (16, 17). In these cases, a revers-
ible epithelial-to-mesenchymal transition (EMT) promotes inva-
siveness and stem cell–like features in cancer cells (18), which are 
driven by a network of embryonic EMT-inducing transcription 
factors (EMT-TFs) of the SNAIL, TWIST, ZEB, and bHLH/E47 
protein families (19). Although melanoma cells are not derived 
from epithelial cells, they nevertheless show EMT-like process-
es that can be observed in culture and that have been associated 
with metastatic spread of the disease (20). In particular, activation 
of the MAPK pathway by oncogenic BRAF or NRAS promotes a 
switch from SNAIL2/ZEB2 expression to TWIST1/ZEB1 expres-
sion, which enhances invasiveness of melanoma cells (21).
One of the major candidate pathways for driving reversible 
phenotype switching is SMAD-dependent TGF-β superfamily sig-
naling, which controls EMT in many cancers (22, 23). Sustained 
expression of EMT-TFs in breast cancer cells is directly regulated 
by autocrine TGF-β signaling (24). In melanoma, several TGF-β 
isoforms and NODAL as well as different BMP ligands were 
shown to be expressed by tumor cells and to promote invasive-
ness in cell culture or in organotypic human skin cultures (6, 7, 
25–27). In support of this, attenuation of TGF-β signaling by over-
expression of SMAD7, an inhibitory SMAD protein (28), or by 
treatment with a small molecule inhibitor reduced bone metasta-
sis formation from cells injected into the cardiovascular system in 
immunocompromised mice (29, 30).
However, other studies reported that melanoma cells exhibit 
partial resistance to the antiproliferative activity of TGF-β fam-
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proliferation rate was comparable between control and cKO mice 
(Supplemental Figure 1, G–I). In support of these results, SMAD4 
knockdown in human melanocytes also resulted in impaired pig-
mentation and decreased expression of melanocyte differentiation 
genes, such as TYRP1, TYRA, and MC1A, while proliferation rates 
were unchanged upon SMAD4 inactivation (Supplemental Figure 
1, J–L). The combined data suggest that Smad4 is not required for 
adult melanocyte survival and proliferation, although it is required 
for normal pigmentation.
Loss of Smad4 prevents tumorigenesis in a genetic mouse mod-
el of melanoma. To investigate the function of TGF-β signaling 
in melanoma, we used genetically engineered mice that harbor 
a Tyr::NrasQ61K transgene in combination with Cdkn4a (p16Ink4a) 
deficiency. Such mice, hereafter termed NrasQ61K Ink4a−/− mice, 
develop hyperplastic lesions marked by ectopic dermal pigmen-
tation and spontaneously form melanomas (36). These were bred 
with Tyr::CreERT2, Smad4fl/fl mice to eventually yield Smad4fl/fl 
NrasQ61K Ink4a−/− offspring, in which TM treatment leads to mela-
nocyte-specific conditional Smad4 ablation in cells marked by 
expression of β-gal (Figure 1A). TM treatment was done at 1 month 
of age, that is, before control mice develop detectable melano-
mas (Figure 1B). As long as Smad4 remained intact (Smad4fl/fl, no 
TM; or Smad4fl/fl + TM, but in the absence of CreERT2), 76% ± 5% 
of hair follicles were associated with ectopic pigmentation. Two 
months after TM injection, the recombination efficiency in such 
hyperplastic lesions was 66% ± 6%, as assessed by counting β-gal/
Pax3 double-positive melanocytic cells. Conditional loss of Smad4 
resulted in a marked decrease of hyperplastic lesions, with only 
13% ± 3% of hair follicles displaying ectopic dermal pigmentation 
(Figure 1, C and D). In these mice, melanocytic, Pax3-positive 
cells were positive for β-gal, suggesting that Smad4 is not essen-
tial for the survival of premalignant melanocytic cells (Figure 1, E 
and F). Importantly, the loss of Smad4 was associated with a sig-
nificant decrease in the number of β-gal–positive skin melanomas 
(diameter ≥ 2 mm), which readily emerged after approximately 
5 months of age in corresponding control mice (Figure 1, G and 
H). Consistent with the decreased skin tumor load, Smad4-cKO 
mice displayed strongly reduced numbers of metastatic lung nod-
ules as compared with control animals (Figure 1I). Consequently, 
overall as well as melanoma-specific survival was highly increased 
in Smad4-cKO mice (Figure 1, J and K). These findings reveal a 
requirement for Smad4 in melanoma formation.
Loss of Smad4 leads to decreased proliferation in established 
skin tumors. To address the cellular mechanism mediated by 
Smad4-dependent signaling in established melanoma, we con-
ditionally deleted Smad4 by TM treatment after the appearance 
of visible tumors (Figure 2A). The phenotype of Smad4 heterozy-
gous animals did not differ from that of Smad4 WT mice. Hence, 
NrasQ61K Ink4–/– Tyr::CreERT2 Smad4fl/WT R26R-LSL-LacZ animals 
were used as control animals for further analyses. High recombi-
nation efficiency was apparent at the day of sacrifice (Figure 2B). 
While apoptosis in recombined melanoma cells was generally 
low in Smad4-cKO mice and comparable to levels seen in control 
melanoma tissue, proliferation was significantly reduced in cKO 
mice, as demonstrated by labeling of β-gal–positive recombined 
cells with the proliferation marker Ki67 (Figure 2, C–E). Thus, 
while Smad4 has no apparent effect on proliferation of normal 
ily factors (31). Moreover, TGF-β–dependent SMAD signaling 
and transcription were not restricted to invasive cells, but were 
also observed in proliferative human melanoma cells (31). Like-
wise, in human tissue samples, nuclear pSMAD2/3, which medi-
ates canonical TGF-β signaling, was detected at all stages of the 
disease, including in benign hyperplastic lesions and cutaneous 
primary melanoma as well as in invasive melanoma (32). Final-
ly, inhibition of SMAD2/3 signaling by SMAD7 overexpression 
not only affected the invasiveness of melanoma cells, but also 
reduced their capacity to grow in vitro and upon transplantation 
into immunocompromised mice (29).
The combined data suggest that SMAD-mediated signaling 
may exert various functions in melanoma, which are likely influ-
enced by the cellular context and the TGF-β superfamily ligands 
the tumor cells are exposed to (23). Therefore, in an attempt 
to mimic the tumor microenvironment with respect to TGF-β–
dependent SMAD signaling, we treated melanoma cells with 
various combinations of TGF-β family factors and addressed the 
relevance of overall TGF-β/SMAD signaling in melanoma in vivo 
by means of a genetic mouse model, in which tumors develop 
spontaneously within an undisturbed 3D environment. Searching 
for factors modulating the proliferative and invasive capacities 
of melanoma cells, we identified SMAD7 as a repressor of a tran-
scriptional program associated with concomitant MITFhiAXLhi 
expression. In fact, conditional Smad7 deletion in vivo resulted 
in the emergence of a MITFhiAXLhi subpopulation of cells that 
were simultaneously proliferating and invasive and associated 
with increased macrometastasis formation. These experiments 
identify integrated SMAD signaling as a key driver of melanoma 
initiation, growth, and metastatic progression, pointing to a new 
therapeutic vulnerability in melanoma.
Results
Conditional deletion of Smad4 in the adult melanocytic lineage does not 
impair proliferation and survival. Downstream of TGF-β superfam-
ily signaling, the receptor-associated SMAD (R-SMAD) proteins 
SMAD2/3 and SMAD1/5/8, are activated by TGF-β/ACTIVIN/
NODAL or BMP signals, respectively (33, 34). Activated R-SMADs 
interact with the common partner SMAD4, which is essential for 
all canonical transcriptional responses (35). To address whether 
SMAD signaling is essential for homeostasis of normal melano-
cytes, we injected 6-week-old Tyr::CreERT2 Smad4fl/fl R26R-LSL-
LacZ mice with tamoxifen (TM) intraperitoneally for 5 days prior 
to dorsal hair plucking, which induces synchronized hair growth 
(Supplemental Figure 1, A–C; supplemental material available 
online with this article; https://doi.org/10.1172/JCI94295DS1). 
Recombination efficiency was 61% ± 5%, as assessed by count-
ing the percentages of recombined, β-gal–positive hair follicles 
(Supplemental Figure 1D). Unlike in control animals, TM-induced 
conditional KO (cKO) of Smad4 resulted in hypopigmentation of a 
subset of regenerating hairs (Supplemental Figure 1, E and F). How-
ever, this pigmentation defect was not associated with a reduction 
in the number of hair bulbs containing recombined melanocytes 
(β-gal/Dct double-positive) between control (Tyr::CreERT2 R26R-
LSL-LacZ) and cKO (Tyr::CreERT2 Smad4fl/fl R26R-LSL-LacZ) ani-
mals upon plucking (Supplemental Figure 1, F and G). Additional-
ly, the number of recombined melanocytes per hair bulb and their 
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To clarify the mechanism underlying Smad4-dependent cell 
cycle control, we determined changes in the expression of several 
cyclin-dependent protein kinase (CDK) inhibitors after siRNA- 
mediated Smad4 silencing in melanoma cell lines derived from 
cells (Supplemental Figure 1, H, I and K), it controls proliferation 
of melanoma cells, indicating that the combined action of TGF-β 
superfamily members promotes, rather than counteracts, tumor 
growth in vivo.
Figure 1. Conditional Smad4 deletion in a genetic mouse model of melanoma prevents tumorigenesis. (A) Schematic of the melanoma mouse model har-
boring Tyr::NrasQ61K, Ink4a−/−, Tyr::CreERT2, floxed Smad4, and R26R Cre-reporter alleles. (B) Experimental strategy used to analyze early loss of Smad4 before 
appearance of visible melanomas. Control mice either lacked the Tyr::CreERT2 allele or were not treated with TM. (C) Representative H&E staining of trunk 
skin sections of control and cKO mice at day of sacrifice showing ectopic dermal hyperpigmentation. (D) Quantification of the percentage of hair follicles 
exhibiting ectopic pigmentation in control (nontreated with TM) and cKO mice (n = 350 hair follicles quantified from 6 different mice). (E) Immunofluores-
cent staining for Pax3 (control, nontreated with TM) and Pax3+β-Gal+ (cKO) on back skin sections at 6 months to quantify extent of dermal hyperplasia. Open 
arrowheads indicate Pax3+ cells, white arrowheads Pax3+β-Gal+ cells. (F) Quantification of the percentage of dermal Pax3+ cells between hair follicles (n = 300 
hair follicles from 6 different cKO and control mice). (G) Macroscopic pictures of a control and a Smad4-cKO littermate 6 months after Smad4 ablation. (H) 
Quantification of recombined primary tumor numbers per control (n = 12) and cKO (n = 11) mice at the day of sacrifice. (I) Quantification of lung macrometas-
tases counts at day of sacrifice using macroscopic pictures and staining on sections (n = 12). (J and K) Kaplan-Meier curves displaying overall and melanoma- 
specific survival, respectively, of control (n = 12) and Smad4-cKO (n = 17) animals. Vertical bars (K) indicate mice censored because of melanoma-unrelated 
tumors developing due to constitutive loss of Ink4a. Data are represented as a mean of 3 independent experiments ± SEM (H and I) and ± SD (D and F).  
***P < 0.001, unpaired Student’s t test (D, F, H, I), log-rank Mantel-Cox test (J and K). Ctrl, control; HF, hair follicle. Scale bars: 50 μm (E); 500 μm (C).
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Figure 2. Loss of Smad4 leads to decreased proliferation in established skin tumors. (A) Experimental strategy used to analyze the deletion of Smad4 
in already established skin melanomas. Mice carrying Tyr::NrasQ61K Ink4a–/– Tyr::CreERT2 Smad4fl/WT R26R::LacZ or Tyr::NrasQ61K Ink4–/– Smad4fl/fl R26R::LacZ 
were used as controls. (B) Recombination efficiency was calculated by counting percentages of β-gal+Pax3+ cells on primary tumor sections (n = 6, cKO and 
control; Tyr::NrasQ61K Ink4a–/– Tyr::CreERT2 Smad4fl/WT R26R::LacZ treated with TM). (C) Representative immunofluorescent costaining of Ki67 with β-gal on 
skin melanoma sections 72 hours after conditional deletion of Smad4. White arrowheads indicate Ki67+β-Gal+ cells; open arrowheads indicate Ki67–β-Gal+ 
cells. (D) Quantification of Ki67+β-Gal+ cells in control (Tyr::NrasQ61K Ink4a–/– Tyr::CreERT2 Smad4fl/WT treated with TM) and cKO mice (n = 4). (E) Quantification 
of apoptotic cells by IHC for activated caspase-3 on skin sections of control and cKO mice (n = 4). (F) Quantitative reverse transcription PCR (RT–qPCR) 
for expression of multiple G1 cell cycle inhibitors in RIM3 (n = 3) and RIM4 (n = 2) cell lines after siRNA treatment. (G) Western blot performed on nuclear 
extracts from RIM3 for cell cycle regulator Cdkn1a (p21Waf1), Cdkn2c (p18Ink4c), and Cdkn2a (p16Ink4a) protein expression. (H) Percentage of S phase cells upon 
SMAD4 knockdown in various human melanoma cell lines. (I) RT-qPCR analysis of the same cell cycle regulators in M010817 human melanoma cell line. 
Data are represented as the mean ± SEM (D) and ± SD (B, E, F, H, I). **P < 0.01; ***P < 0.001. RT-qPCR results are shown as mean ± SD of 3 biological 
replicates. For Western blots, representative examples are shown. P values calculated with unpaired Student’s t test (B, D, E, F, H, I). Mel, Melan-A mouse 
melanocyte line. Scale bar: 50 μm.
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anoma cells are expressed by the tumor cells themselves, where 
they induce their own expression through a positive amplification 
loop (27, 39–41). Likewise, several TGF-β superfamily members, 
notably TGF-β2 and BMP7, were concomitantly expressed by 
tumors derived from NrasQ61K Ink4a−/− mice (Supplemental Figure 
3A). Thus, we functionally investigated these factors to identify 
ligands potentially responsible for melanoma cell proliferation. 
Cell cycle analysis of 2 cell lines (M010817 and 501Mel) revealed 
that, among the factors analyzed, BMP7 induced cell cycle pro-
gression. The percentages of cells in the S-phase were significantly 
increased from, respectively, 18 ± 1% and 18% ± 2% in control to 
28% ± 3% and 27% ± 2% after exposure to BMP7 (Supplemental 
Figure 3, B and C). In contrast, the other TGF-β superfamily fac-
tors tested suppressed proliferation in human melanoma cells, as 
previously reported (Supplemental Figure 3, B and C) (6, 27, 42). 
In agreement with these earlier reports, human melanoma cells 
exposed to TGF-β2, NODAL, or BMP4 also changed their mor-
phology and exhibited a decreased cell-substrate adherence while 
BMP7 did not (Supplemental Figure 3D).
To substantiate the above findings, we correlated expression 
levels of BMP7 and TGFB2 with RNA-Seq data obtained from 
various proliferative and invasive human melanoma cell lines in 
culture. Among others, TGFB2 mRNA was robustly expressed in 
patient-derived cell cultures representing an invasive melano-
NrasQ61K Ink4a–/– mice (RIMs) (37). Of all CDK inhibitors tested, 
Cdkn2b (p15Ink4b) and Cdkn2c (p18Ink4c) were significantly upregu-
lated in Smad4-knockdown cells (Figure 2, F and G).
To address whether SMAD4 regulates proliferation also in 
human melanoma cells, we performed SMAD4 knockdown exper-
iments in various human melanoma cell lines. Of note, in all cell 
lines tested, the percentages of cells in the S-phase were decreased 
after siSMAD4 transfection relative to siControl transfection, like-
ly because downregulation of SMAD4 expression counteracted 
cell cycle progression by repressing G1/S transition (Figure 2H and 
data not shown). Importantly, in data that were analogous to those 
obtained with murine melanoma cells, cell cycle arrest induced by 
SMAD4 inactivation was associated with increased expression of 
CDKN2B (p15INK4b) and CDKN2C (p18INK4c), while the expression 
of other CDK inhibitors was not altered (Figure 2I and Supple-
mental Figure 2, A–D).Thus, both in mouse and human melanoma 
cells, SMAD4-mediated signaling appears to control proliferation 
by suppressing expression of the respective CDK inhibitors.
BMP7 signaling promotes melanoma cell growth. Until now, 
members of the TGF-β superfamily have been associated with 
cytostatic and/or proinvasive functions in melanoma cells (38). 
However, our in vivo data indicate that one or more factors that 
signal through Smad4 must have a proproliferative role. Most of 
the TGF-β family ligands known to elicit responses in human mel-
Figure 3. Low SMAD7 levels are associated with poor prognosis in human melanoma patients. (A) P values are given for Kaplan-Meier analysis com-
paring percentage of overall survival of melanoma patient cohorts (n = 454) based on TCGA data for 36 identified transcripts of TGF-β/BMP pathway 
components. For each gene, low/high expression levels were based on transcript levels found in the bottom and top 50 patients, respectively. Red bars 
show that lower levels of the transcripts correlate with poor survival. whereas black bars indicate that higher levels of the transcript correlate with poor 
survival. (B and C) Kaplan–Meier curves comparing overall percentage survival and patient survival rate in stages II, III, and VI with respect to SMAD7 tran-
script levels based on 454 patients. (D) Significantly changed top 10–ranking GeneGo process networks associated with low/high SMAD7 expression based 
on MetaCore Database.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
6 jci.org
ma phenotype (WNT5Ahi, AXLhi, ZEB1hi, SOX9hi) (Supplemental 
Figure 3E). In contrast, markers for proliferative melanoma cells 
(SOX10hi, MITFhi) correlated with BMP7 expression levels (Supple-
mental Figure 3E).
Since activation of R-SMADs is required for canonical TGF-β 
signaling, we investigated whether proliferative versus invasive 
ligands preferentially signal through specific SMADs. Western 
blot analysis for pSMAD1/5/8 and pSMAD2/3 (indicators of BMP 
and TGF-β signaling activity, respectively) verified signaling spec-
ificity between different TGF-β superfamily members in human 
melanoma cells (Supplemental Figure 3, F–H). Remarkably, both 
BMP4 and BMP7 signaled through SMAD1/5/8 phosphorylation, 
although BMP4 counteracted proliferation and induced an inva-
sive program when added to melanoma cells, whereas BMP7 
increased the percentage of cells in the S phase (Supplemental Fig-
ure 3, B–D and H). Thus, the distinct biological activities of TGF-β 
superfamily members cannot simply be explained by differential 
usage of the known canonical SMAD signaling pathways.
Loss of SMAD7 is clinically relevant and associated with a MITFhi 
AXLhi transcriptional state. Our data show that certain TGF-β 
superfamily factors expressed in melanoma display opposite 
effects on cell growth and invasiveness. In an attempt to identi-
fy modulators and effectors of TGF-β/SMAD signaling possibly 
relevant for melanoma progression, we first examined RNA-Seq 
and clinical data from the skin cutaneous melanoma dataset of 
The Cancer Genome Atlas (TCGA-SKCM) (43). Survival analysis 
of TCGA-SKCM showed that, among 36 SMAD signaling compo-
nents, the inhibitory SMAD protein SMAD7 stood out as the clin-
ically most relevant factor (Figure 3A). In fact, patients with low 
SMAD7 transcript levels had significantly shorter overall surviv-
al as compared with those having high SMAD7 transcripts levels 
(P = 0.0356) (Figure 3B). The SMAD7hi and SMAD7lo patient 
cohorts did not exhibit obvious differences with respect to clini-
cally relevant BRAF and NRAS mutations (data not shown). The 
difference in survival was even more evident when comparing 
among the SMAD7lo and SMAD7hi groups those patients that dis-
played advanced stage disease at the time of analysis (stages II–IV) 
(P = 0.0125) (Figure 3C). Furthermore, gene ontology (GO) anal-
ysis using differential gene signatures of SMAD7lo and SMAD7hi 
patients revealed that categories crucial for melanoma biology, 
such as regulation of EMT, cell adhesion and migration, and 
cytoskeletal remodeling as well as upregulation of MITF, were 
significantly enriched (Figure 3D). Finally, we performed immu-
nofluorescent staining for SMAD7 and the human melanoma 
marker S100A on 13 different patient samples and quantified the 
percentage of SMAD7/S100A double-positive cells at superficial 
(upper layer of epidermis, upper nodules) versus deep sites (deep-
er nodules and dermis) of primary melanoma samples (Supple-
mental Figure 4, A and B). While SMAD7 was strongly expressed 
in superficial regions of melanoma nodules, its expression was sig-
nificantly weaker or absent in deeper areas and in dermal invasive 
melanoma cells, suggesting that SMAD7lo cells may be predomi-
nantly associated with the invading front of human melanoma.
To address the physiological role of SMAD7 and its poten-
tial association with TGF-β signaling in melanoma cells, we 
first reduced SMAD7 levels using siRNAs. This led to a signifi-
cant increase in the levels of both pSMAD2/3 and pSMAD1/5/8, 
demonstrating the capacity of SMAD7 to inhibit canonical TGF-β 
signaling in melanoma cells (Supplemental Figure 4, C–E). To 
characterize the molecular pathways regulated by SMAD7-medi-
ated signaling in melanoma, M010817 cells treated with siSMAD7 
or siControl were subjected to RNA-Seq. Similarly to the TCGA 
patient analysis (Figure 3D), the GO analysis by ClueGO demon-
strated significant enrichments in pathways associated with cell 
cycle core components and cell-cell adhesion (Figure 4, A and B, 
Supplemental Figure 4F, and Supplemental Table 1) (44). Specifi-
cally, a comprehensive EMT program, including cell-cell adhesion 
molecules and transcriptional regulators associated earlier with 
a melanoma invasive gene program (45) was upregulated upon 
knockdown of SMAD7 (Figure 4, C and D, and Supplemental 
Table 2). In addition, however, there was also a significant overlap 
between SMAD7-dependent transcriptional changes and a previ-
ously described proliferative melanoma gene signature (45) (Fig-
ure 4, C and D, and Supplemental Table 3).
An increase in the expression of EMT regulators has been 
reported to anticorrelate with an MITFhi gene expression program 
(14, 46). Moreover, the ratio of MITF/AXL expression has been 
used to define proliferative versus invasive behaviors of melano-
ma cells (3, 14). Therefore, we next assessed which of the genes 
that constitute the published MITFhi and AXLhi programs were dif-
ferentially expressed in the TCGA-SKCM–based SMAD7lo patient 
group and in SMAD7-silenced human melanoma cells, respective-
ly (13). Surprisingly, genes of both the MITF and the AXL program 
were mostly upregulated in SMAD7lo patient melanomas or upon 
loss of SMAD7 in melanoma cells (Figure 4, E–H, Supplemental 
Table 4). These data suggest that melanoma cells with decreased 
SMAD7 levels exhibit a MITFhiAXLhi transcriptional state.
Loss of SMAD7 boosts proinvasive TGF-β/NODAL signaling in 
the presence of proproliferative BMP7. According to our gene expres-
sion analysis, SMAD7 appears to be implicated in both cell cycle 
and cell adhesion/EMT control in melanoma. To functionally test 
this hypothesis, we assayed the effect of siRNA-mediated SMAD7 
knockdown in the context of combinatorial TGF-β superfamily 
signaling. Control experiments with SMAD7 WT cells showed that 
individual TGF-β2 or NODAL treatment reduced proliferation 
and cell-substrate adhesiveness of human melanoma cells, which 
was accompanied by increased invasiveness in a Matrigel Tran-
swell assay and upregulation of an EMT gene expression signature 
characteristic for invasive melanoma (Figure 5, Supplemental Fig-
ure 5, and Supplemental Figure 6). In contrast, BMP7 stimulated 
proliferation, prevented cell detachment from the substrate, and 
suppressed the EMT signature even when added together with 
TGF-β2/NODAL (Figure 5, A–D and G, Supplemental Figure 5, and 
Supplemental Figure 6). Thus, in the presence of TGF-β2/NODAL, 
proproliferative BMP7 is dominant and able to override the cyto-
static effects of TGF-β2/NODAL in human melanoma cells.
We next performed similar cell cycle analyses and invasion 
assays in the context of SMAD7 knockdown. Although downreg-
ulation of SMAD7 did not alter the cell cycle–promoting effect of 
BMP7 in human melanoma cells, SMAD7 knockdown in the pres-
ence of BMP7 reversed the cell cycle arrest observed after TGF-β2 
treatment, hence rendering treatment with TGF-β2 compatible 
with cell proliferation (Figure 5, A–C, and Supplemental Figure 5, 
A–C). In contrast to the capacity of BMP7 to override the cytostat-
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ic effect of TGF-β2, however, BMP7 treatment only partially coun-
teracted the loss-of-adhesion phenotype mediated by TGF-β2/ 
siSMAD7. Indeed, in BMP7/TGF-β2/siSMAD7-treated cultures, 
there was still a significant increase in the number of cells in sus-
pension as compared with in control cultures (Figure 5D and Sup-
plemental Figure 5D). Consistent with these observations, siSMAD7 
treatment of cells concomitantly exposed to TGF-β2 and BMP7 
restored an EMT gene expression signature characteristic of inva-
sive melanoma cells (Figure 5G) and increased invasion in Matrigel, 
thereby reinforcing the proinvasive properties of TGF-β2 (Figure 5, 
E and F, and Supplemental Figure 5E). Similar results were observed 
upon combinatorial treatment with NODAL. While BMP7/NODAL- 
treated cells had a noninvasive phenotype, BMP7/NODAL/ 
siSMAD7-treated cells maintained their proliferative capacity, but 
displayed reduced cell adhesion and an EMT signature reminiscent 
of invasive cells (Supplemental Figure 6). Thus, reducing SMAD7 
levels does not alter proliferation in vitro, but boosts the proinvasive 
activity of TGF-β2/NODAL even in the presence of BMP7.
To substantiate that these cells retain the capacity to prolif-
erate and be invasive, we pulsed human melanoma cells with the 
thymidine analogue EdU after 48 hours of silencing SMAD7 in 
the presence of BMP7 and TGF-β2 (Figure 6A). Furthermore, we 
Figure 4. Low SMAD7 levels are associated with altered cell adhesion and cell cycle programs in human melanoma cell lines. (A) Heatmap showing 
genes differentially expressed in SMAD7 knockdown and control M010817 cells (3557 genes, row z-score from 3 replicate RNA-Seq experiments). The gene 
list was generated using a 1.5-fold-change cut-off, and a P value of 0.05. Of these, 1586 were upregulated and 1971 downregulated. (B) GO analysis based 
on differentially regulated genes upon SMAD7 knockdown. Each individual node shows an enriched GO term (P < 0.05) (Corrected with Bonferroni’s step 
down procedure). BP, biological process; MF, molecular function; CC, cellular component. A fully labeled version is given in Supplemental Figure 4F. (C) 
Venn diagram shows the upregulated and downregulated common genes involved in previously described Verfaillie invasive (Inv.) and proliferative (Pro.) 
program. (D) Heatmap of differentially expressed genes associated with Verfaillie invasive and proliferative programs (proliferative program, n = 165/627, 
invasive program. n = 203/695) (44) Red, increased; blue, decreased expression. (E and G) Venn diagram showing the overlap between MITFhi and AXLhi 
gene expression programs derived from patient melanoma samples obtained by single-cell RNA sequencing (16) with genes changed between low/high 
expressing SMAD7 patients or upon siRNA-mediated knockdown of SMAD7 in M010817. (F and H) Heatmaps indicate differentially expressed MITF and 
AXL program genes, respectively. For gene lists corresponding to D, F, and H, see Supplemental Tables 3 and 4, respectively.
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Deregulated TGF-β/SMAD signaling can alter MITF expres-
sion depending on the melanoma cell line (47). Moreover, the 
ratio of MITF/AXL expression levels has been used to distinguish 
proliferative and invasive melanoma cells (3, 14). Therefore, we 
also assessed the percentages of cells expressing high versus low 
levels of MITF, together with AXL expression, upon combinatorial 
TGF-β superfamily treatment (Figure 6, B and D). In cultures left 
tested to determine whether proliferative cells expressed ZEB1, 
which is characteristic of invasive melanoma cells (21). Strikingly, 
double staining revealed that BMP7/TGF-β2/siSMAD7–treated 
cultures contained significantly higher numbers of EdU and 
ZEB1 double-positive cells (23% ± 3%) in comparison with BMP7/
TGF-β2–treated (9% ± 2%) or untreated control cultures (4% ± 
1%) (Figure 6, B and C).
Figure 5. Loss of Smad7 boosts proinvasive TGF-β/NODAL signaling in the presence of proproliferative BMP7. (A) Growth curves of M010817 cells treated 
either with TGF-β2 (10 ng/μl), BMP7 (100 ng/μl), or both, with or without siRNA-mediated SMAD7 knockdown (siS7) (n = 1 independent experiment and 3 
technical replicates). (B) Bar plots show the number of cells at day 3 after various treatments (n = 1 independent experiment and 3 technical replicates). (C) 
Percentage of S phase cells measured 3 days after ligand treatment based on propidium iodide and EdU staining. Treatment with BMP7 resulted in escape 
of cells from the TGF-β2–mediated cell cycle arrest and increased proliferation. (n = 3 independent experiments). (D) Quantification of substrate adherence 
capacity of M010817 cells upon different treatments. TGF-β2–mediated cell detachment was suppressed by BMP7. The percentage of BMP7/TGF-β2/ 
siSMAD7–treated cells in suspension increased as compared with BMP7/TGF-β2–treated cells (n = 2 independent experiments). (E) Matrigel-based invasion 
assays of siControl and siSMAD7-depleted M010817 cells with combinatorial treatments. After invading cells had been counted in 5 random microscopic 
fields in each assay, the results were normalized and are presented as an invasion index (n = 2 independent experiments). (F) Photographs of cells invading 
the membrane, stained with Hoechst. (G) Heatmap shows qRT-PCR analysis for selected EMT genes under ligand treatments (n = 2 independent exper-
iments and 3 technical replicates). The gene expression levels are represented as fold-change values transformed to log2 format compared with control. 
Color represents expression after normalization to nontreated control cells. Data are represented as a mean of 3 (C), 2 (D and E), or 1 (A and B) independent 
experiments ± SD. **P < 0.01; ***P < 0.001, 1-way ANOVA followed by Tukey’s multiple comparison test.
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Figure 6. Loss of SMAD7 promotes emergence of proliferative-invasive MITFhiAXLhi melanoma cells in vitro. (A) Experimental design used in this study. 
Proliferative M010817 cells were exposed to combinatorial ligand treatment over 3 days. Cells were pulsed with EdU, followed by immunofluorescent 
staining (B) Representative IF images. White arrowheads mark ZEB1+EdU+ or MITFhiAXL+ cells. Open arrowheads mark ZEB1–EdU+ or MITFhiAXL– cells. (C) 
Quantification of single- and double-labeled cells for ZEB1 and EdU (n = 3). (D) Quantification of cells expressing AXL, MITFhi, or both (n = 3). (E) Experi-
mental design and sorting approach for functional analysis of MITFhiAXL+ cells. (F) Quantification of EdU+ proliferative cells expressing MITFhiAXL and  
expressing MITFloAXL by FACS (n = 3). (G, I, K) Enrichment for the AXL+EdU+ subpopulation in BMP7/TGF-β2/siSMAD7–treated cells as shown by FACS  
(n = 3) (yellow quadrant [Q2)] AXL+EdU+, gray quadrant [Q4] AXL+EdU–). (H, J, L) Histograms show the MFI values for MITF expression in AXL+EdU+ versus 
AXL+EdU– cells. (M) FACS analysis of cells stained with an AXL antibody following TGF-β2 and BMP7 treatment with or without siRNA-mediated SMAD7 
knockdown. (N) Matrigel assays of sorted AXL+ and AXL– cells. (O) MITF MFI of AXL+ and AXL– cells following combinatorial treatment. Mean of 3 (C, D, 
F) or 2 independent experiments (N and O) ± SD. ***P < 0.001, unpaired Student’s t test (C, D, F, N, O). Scale bars: 50 μm.
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tive versus AXL-negative cells obtained from different culture 
conditions (Figure 6E and Supplemental Table 5). In control and 
siSmad7-treated cultures as well as in the presence of TGF-β2 
and BMP7, the majority of EdU-positive cells did not express AXL 
(Figure 6, F, G, I). In contrast, cultures with concomitant BMP7/
TGF-β2/siSMAD7 treatment showed a significant increase in the 
percentage of EdU-positive proliferating cells expressing AXL 
(Figure 6, F and K). Moreover, MITF MFI was higher in AXL/
EdU double-positive cells as compared with AXL-positive/EdU- 
negative cells (Figure 6, H, J, and L, and Supplemental Table 6). 
untreated, exposed to various combinations of TGF-β superfam-
ily factors, or treated with siSMAD7 in the absence of exogenous 
TGF-β factors, AXL-positive cells were MITFlo, and only a minor 
fraction of cells expressed both AXL and high levels of MITF. In 
contrast, upon concomitant BMP7/TGF-β2/siSMAD7 treatment, 
the number of cells double positive for AXL and high MITF was 
significantly increased to 18% ± 3%.
To determine the biological properties of this MITFhiAXLhi 
cell subpopulation, we first assessed the rate of EdU incorpora-
tion and MITF expression levels in FACS-separated AXL-posi-
Figure 7. Loss of Smad7 promotes emergence of proliferative-invasive MITFhiAXLhi melanoma cells in vivo. (A) Schematic of the melanoma mouse 
model used to analyze the effect of Smad7 conditional deletion in Tyr::CreERT2 Tyr::NrasQ61K INK4a−/− R26R-LacZ mice. (B) Experimental strategy used to 
analyze the proliferation rate by EdU injection upon Smad7 loss. (C) Quantification of the number of skin melanomas of control and Smad7-cKO mice 
(n = 12). (D and E) Immunostaining and quantification of EdU+Zeb1+ cells in Smad7-cKO and control primary tumors (n = 3). Gray and white bars indicate 
single Zeb1+ and EdU+ cells, respectively. Yellow bars represents percentages of EdU+Zeb1+ cells. White arrowheads in the images indicate EdU+Zeb1+ cells, 
open arrowheads EdU+Zeb1– cells. (F–H) Quantification and immunostaining of MitfhiAxl+ cells in cKO and control primary tumors. Percentages of Mitfhi 
Axl+ cells calculated over total number of Mitfhi and Mitflo cells (n = 10). Yellow bars represent percentages of Mitfhi cells that are Axl+. White arrowheads 
indicate MitfhiAxl+ cells, open arrowheads MitfhiAxl– cells. Data are represented as the mean ± SEM. ***P < 0.001, unpaired Student’s t test (C–F). Epi, 
Epidermis. Scale bars: 50 μm.
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proliferative MITFhiAXLhi cells with invasive capacity, which pos-
sibly contributes to melanoma cell aggressiveness.
Loss of Smad7 in vivo increases the number of cells with both inva-
sive and proliferative features. Our cell culture data revealed the 
presence of cells that acquired both invasive and proliferative fea-
tures upon SMAD7 inactivation. To corroborate these findings in 
an in vivo setting, we used NrasQ61K Ink4a–/– mice that also carried 
a floxed allele of Smad7 (48), the Tyr::CreERT2 transgene, and the 
R26R-LSL-LacZ reporter gene (Figure 7, A and B). TM-mediated 
Cre-activation at 1 month of age resulted in efficient recombina-
tion and depletion of Smad7 protein in Dct-expressing melanoma 
cells (Supplemental Figure 7, A–C). Importantly, loss of Smad7 led 
to a substantial increase in the percentage of Dct-positive mela-
nocytic cells coexpressing nuclear pSmad2/3 and pSmad1/5/8, 
demonstrating activation of both canonical SMAD signaling 
pathways (Supplemental Figure 7, D and E). Despite signal acti-
Remarkably, the highest MITF expression levels were detected 
in AXL/EdU double-positive cells upon silencing of SMAD7 in 
BMP7/TGF-β2–treated cultures (Figure 6L).
To study the invasive potential of MITFhiAXLhi cells, AXL- 
positive and AXL-negative cell populations were FACS isolated 
from human melanoma cell lines exposed to the above-mentioned 
conditions, followed by a Matrigel Transwell invasion assay (Fig-
ure 6, E and M). Under most conditions analyzed, the invasive 
capacities of AXL-positive and AXL-negative cells were not signifi-
cantly different. Strikingly, however, the AXL-positive population 
present in BMP7/TGF-β2/siSMAD7–treated cultures displayed the 
highest invasiveness among all cell populations analyzed (Figure 
6N). Moreover, MITF levels were markedly increased in these 
AXL-positive cells when compared with the other cell populations 
(Figure 6O). Thus, reducing SMAD7 levels in the presence of com-
binatorial BMP7/TGF-β2 treatment leads to the appearance of 
Figure 8. Reduced Smad7 expression 
promotes metastatic spread of mela-
noma in vivo. (A) Kaplan-Meier curves 
comparing melanoma-specific survival 
of control and Smad7-cKO animals (n 
= 35 cKO, n = 30 control). (B) Represen-
tative photographs of indicated organ 
from Smad7-cKO and control mice. (C) 
Immunofluorescent staining for Smad7 
and Dct at the sites of distant metas-
tasis in Smad7-cKO and control mice. 
Note absence of Smad7 expression in 
pigmented Dct+ areas. (D–F) Quantifica-
tion of macrometastasis in lung, spleen, 
and liver in Smad7-cKO and control 
littermates (lung, n = 21 cKO, n = 31 
control; liver, n = 24 cKO, n = 12 control; 
spleen, cKO n = 32, control n = 25). (G) 
Experimental strategy used to analyze 
the effect of local Smad7 loss in Tyr::N-
RasQ61K Ink4a−/− Tyr::CreERT2 R26R::LacZ 
mice by 4-OHT administration to the 
skin. (H) Quantification of lung macro-
metastasis, in which Smad7 has been 
locally deleted in the skin of 3-week-old 
mice (n = 11 cKO, n = 12 control). Data are 
represented as a mean of 3 independent 
experiments ± SEM. **P < 0.01; ***P < 
0.001, unpaired Student’s t test (D–F) 
or log-rank Mantel-Cox test (A). met, 
metastasis. Scale bar: 50 μm.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 2 jci.org
cells can overcome restrictions in proliferation by intrinsically 
modulating their response to combinatorial TGF-β superfamily 
signaling. Despite the vast literature on TGF-β eliciting an antipro-
liferative and proinvasive effect in melanoma cells (31, 50, 51), we 
reveal that Smad4-mediated overall canonical TGF-β signaling is 
required for tumor initiation and primarily promotes, rather than 
antagonizes, melanoma cell proliferation in vivo. Consistent with 
these data, we identify BMP7 as a factor stimulating melanoma 
cell proliferation and able to override the antiproliferative and 
proinvasive activity of TGF-β and NODAL. However, invasiveness 
can be triggered in cells exposed to combinatorial TGF-β signaling 
by lowering levels of the inhibitory SMAD protein SMAD7. Strik-
ingly, activation of integrated TGF-β signaling by SMAD7 inhibi-
tion results in the emergence of an invasive program characterized 
by high AXL and ZEB1 expression in cells maintaining high MITF 
expression and proliferative capacity. Consequently, the increase 
in the number of MitfhiAxlhi cells in Smad7-depleted melanoma is 
associated with massive metastasis formation in vivo. Our find-
ings demonstrate that proliferation is compatible with increased 
invasiveness and continued expression of MITF, revealing a 
mechanism that underpins melanoma aggressiveness.
Our data are compatible with earlier studies suggesting that 
melanoma progression can occur in the absence of phenotype 
switching. Recently, single-cell RNA sequencing revealed the 
presence of a small subpopulation of MITFhiAXLhi cells in every 
human tumor sample assessed, although MITF and AXL expres-
sion were exclusive on the level of the bulk tumor (15). Also, a 
considerable fraction of circulating tumor cells isolated from inva-
sive melanoma patients was MITF positive (52). Widmer and col-
leagues showed that, in cultures of melanoma cells, hypoxia could 
drive invasion without affecting overall proliferation (53). Further-
more, cells in invasive cell clusters did not alter MITF expression 
during a process referred to as cooperative invasion (54). Final-
ly, time-lapse microscopy in vitro and ex vivo demonstrated that 
invading melanoma cells in culture do not necessarily undergo 
cell cycle arrest and actively proliferate regardless of their MITF 
expression status (55). Our study now reveals how a cellular state 
of simultaneous proliferation and invasion can be achieved by 
modulation of combinatorial TGF-β signaling in melanoma cells. 
Conceivably, changes in overall TGF-β signal activity and thus 
emergence of invasive-proliferative MITFhiAXLhi cells during mel-
anoma progression are dependent on the composition of growth 
factors, the availability of nutrients and/or oxygen in the microen-
vironment, and notably, the regulation of downstream signaling 
molecules such as SMAD7.
It is well established that the biological effects of TGF-β super-
family signaling are context dependent, but how specific respons-
es to TGF-β family factors are controlled is still largely unknown 
(23). In melanoma, several TGF-β superfamily factors, including 
TGF-β, ACTIVINA, NODAL, BMP2, BMP4, and BMP7, are known 
to be expressed and to activate signaling in an autocrine manner 
(27, 41, 56–58). However, BMP7 promoted proliferation, whereas 
BMP4 induced cell cycle arrest in melanoma cells at concentra-
tions at which both factors activated the pSMAD1/5/8-branch 
of TGF-β signaling to a comparable extent. In agreement with 
other studies (6, 42, 59), cell cycle arrest was also induced upon 
treatment with either TGF-β or NODAL, which, unlike BMP4, act 
vation, however, deletion of Smad7 neither had an overt effect on 
hyperplastic dermal lesions (data not shown) nor on the number 
of skin melanomas emerging during disease progression (Figure 
7C). Consistent with this, EdU incorporation was not significantly 
altered in Smad7-cKO tumors as compared with tumors of con-
trol mice (34% ± 1% vs. 37% ±3%) (Figure 7D). Next, we assessed 
Zeb1 expression in primary tumors of NrasQ61K Ink4a–/– mice after 
EdU application. Intriguingly, the number of Zeb1/EdU dou-
ble-positive cells was significantly higher (16% ± 4%) in primary 
tumors of Smad7-cKO mice when compared with control primary 
tumors (4% ± 2%) (Figure 7, D and E). In addition, we quantified 
the numbers of MitfhiAxl double-positive cells in skin sections of 
Smad7-cKO mice. Hyperplastic lesions of Smad7-cKO mice dis-
played significantly higher numbers of double-positive cells (10% 
± 2%) compared with the control (2% ± 1%). Likewise, in Smad7-
cKO primary tumors, the number of MitfhiAxl double-positive cells 
reached 27% ± 3%, as compared with 6% ± 1% in control primary 
tumors (Figure 7, F–H). Thus, inactivation of Smad7 and a concom-
itant increase in pSmad2/3 and pSmad1/5/8 do not interfere with 
tumor growth in vivo, but boost the appearance of proliferating 
cells expressing the invasive marker Zeb1 and of MitfhiAxlhi cells in 
melanocytic lesions.
Reduced Smad7 expression promotes massive metastatic spread 
of melanoma in vivo. Although Smad7-cKO mice apparently dis-
played unaltered tumor initiation and primary tumor growth, their 
melanoma-free survival was significantly reduced (Figure 8A). In 
fact, they showed a massive metastatic spread to lung, spleen, and 
liver, organs that often are devoid of metastases in tumor-bearing 
control mice (Figure 8B). Pigmented Dct-positive cells in these 
metastases did not express Smad7, indicating their origin from 
Smad7-depleted recombined melanoma cells (Figure 8C and Sup-
plemental Figure 7C). Quantification of the metastatic burden in 
lung, spleen, and liver confirmed the high aggressiveness of mela-
noma caused by Smad7 inactivation (Figure 8, D–F).
In the above experiment, Smad7 inactivation was broad-
ly induced in melanocytic cells by systemic TM treatment. To 
assess whether local depletion of Smad7 is sufficient to promote 
melanoma metastasis formation, we applied 4-hydroxytamoxi-
fen (4-OHT) to the back skin of Tyr::NrasQ61K Ink4a–/– Tyr::CreERT2 
Smad7fl/fl R26R::LacZ mice (Figure 8G). Although recombination 
efficiency in the treated areas was lower than in melanocytic skin 
cells after systemic TM treatment (Supplemental Figure 7, B and 
C), a reduction in overall survival of mice was observed (Supple-
mental Figure 7F). Importantly, at the day of sacrifice, the number 
of lung macrometastases was highly increased upon local Smad7 
depletion, demonstrating the striking metastatic potential of 
Smad7-cKO skin melanoma cells (Figure 8H). Thus, loss of Smad7 
significantly increases the aggressiveness of melanoma in the con-
text of enhanced pSmad2/3 and pSmad1/5/8 signal activation.
Discussion
Phenotype switching, i.e., the reversible switch from a prolifera-
tive MITFhiAXLlo melanoma cell to an invasive MITFloAXLhi cell, is 
thought to represent a key mechanism underlying melanoma pro-
gression (2, 3, 5, 14, 49). In the present study, however, we demon-
strate that phenotype switching is not obligatory for invasion and 
metastatic spread of melanoma cells and that invasive melanoma 
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metastasis formation, which involves the reduction of SMAD7 
levels in the presence of proproliferative and proinvasive TGF-β 
superfamily factors. Although it is currently unknown how SMAD7 
expression is normally regulated in melanoma, targeting SMAD7 
level–dependent emergence of proliferative cells with metastatic 
capacity might represent a powerful treatment strategy, possibly 
in combination with drugs interfering with tumor cell prolifer-
ation. Indeed, high levels of ZEB1 expression, which we show to 
be induced by SMAD7 inactivation, have been associated with 
inherent resistance to MAPKi in BRAFV600E-mutant melanoma 
(46). Likewise, a shift toward AXLhi expression was observed in 
melanoma samples resistant to RAF and MEK inhibition (12, 14, 
15). Importantly, our study provides a system for investigating how 
tumor cell–intrinsic changes independent of phenotype switching 
contribute to malignant progression of melanoma.
Methods
All detailed information on experimental procedures and reagents 
is provided in Supplemental Tables 8, 9, and 10 and Supplemental 
Experimental Procedures.
Mice. All implementations were carried out in Tyr::NrasQ61K Ink4a–/– 
Tyr::CreERT2 R26R::LacZ animals kept on a mixed genetic background. 
Animals homozygous for the floxed Smad7 (B6.Cg-Smad7tm1.1Ink/J) (48) 
allele or the floxed Smad4 allele (Smad4tm2.1Cxd/J) (67) were mated 
with mice heterozygous for the respective floxed allele or alleles and 
carrying the TM-inducible CreERT2 recombinase under the control of 
a Tyrosinase promoter (mice provided by L. Chin, The University of 
Texas MD Anderson Cancer Center, Houston, Texas, USA). Geno-
typing was done by PCR on genomic DNA (QIAGEN Taq PCR Core 
Kit 201225) using the primer pairs indicated in Supplemental Table 7. 
DNA was prepared, and the reactions were carried out as described 
(48, 67). The presence of the various alleles did not change the expect-
ed sex, and Mendelian inheritance ratio was found. Mice were exam-
ined frequently and sacrificed at an end point defined by adverse clini-
cal symptoms, such as multiple skin tumors (diameter > 5 mm), weight 
loss (>15%), or hunched posture.
Data and software availability. All RNA-Seq data were deposited 
in the NCBI’s Gene Expression Omnibus database (GEO GSE113472).
Statistics. All data were reported either as mean ± SEM or mean ± 
SD. Results were evaluated using the statistical tests indicated in the 
figure legends. P values and the number of independent experiments 
are indicated in figure legends. P < 0.05 was considered statistical-
ly significant. Survival curves and metastasis were investigated by 
Kaplan-Meier analysis (Unistat) of H-score, which were compared by 
univariate and multivariate Cox regression (Stata). Quantifications of 
immunofluorescent staining were done on sections of at least 3 differ-
ent mice. For each animal, 3 different sections and, for each section, 
300–500 label-positive cells were counted.
Study approval. Primary human materials were provided by the 
Tumor Biopsy and the Live Cell Biobanks of the University Research 
Priority Program (URPP) Translational Cancer Research (Mitchell P. 
Levesque, University Hospital Zurich). Biobanking of surplus, human 
material from consenting melanoma patients was performed accord-
ing to the Declaration of Helsinki on Human Rights and was approved 
by the IRB of Zurich (EK.647/800). All research on surplus human 
material was conducted under IRB approval KEK-Zh.Nr 2014-0425. 
To ensure patient confidentiality, no information on age, gender, or 
through pSMAD2/3 rather than pSMAD1/5/8. Of note, however, 
nuclear pSMAD2/3 activity is not only present in TGF-β–treated 
arrested cells, but also readily detectable in proliferative melano-
ma cells in vitro and in vivo (6, 31, 32). Furthermore, loss of SMAD7 
enhanced both pSMAD1/5/8 and pSMAD2/3 levels in melanoma 
cell cultures and in our melanoma mouse model, but predomi-
nantly boosted TGF-β/NODAL–induced invasiveness rather than 
BMP7-induced proliferation. Thus, the phenotype obtained upon 
reducing SMAD7 in the context of combinatorial TGF-β superfam-
ily signaling cannot simply be explained by preferential usage of 
either pSMAD2/3 or pSMAD1/5/8 signaling.
Our finding that BMP7 acts as a proproliferative factor in mel-
anoma even in the presence of TGF-β/pSMAD2/3 signaling is in 
line with studies in systems other than melanoma, in which BMP7 
was reported to override effects of TGF-β. For instance, TGF-β/
NODAL and BMP7 counterregulate each other during pathophysi-
ological processes in various organs, such as lung, liver, and kidney 
(60–62). In breast cancer cells, BMP7 inhibits expression of TGF-β–
activated genes associated with EMT, resulting in a significant 
reduction in TGF-β–triggered cell migration and invasiveness in 
culture (63), reminiscent of our findings in melanoma. It remains 
to be shown whether in these cases the balance between integrat-
ed BMP7- and TGF-β–dependent signaling outcome can be tipped 
by modulation of SMAD7 activity in a manner similar to what we 
observed in melanoma, where an EMT gene expression signature, 
loss of cell-substrate adhesion in vitro, invasiveness, and metasta-
sis formation in vivo were all promoted upon SMAD7 inactivation 
in spite of the presence of BMP7 and pSMAD1/5/8 activity.
Our experiments indicate that overall canonical TGF-β/
SMAD signaling is a potent promoter of melanoma progression 
already at early stages of the disease. Unlike depletion of TGFbRII, 
which interferes with pSMAD2-mediated signaling and results in 
hair graying associated with disturbed melanocyte stem cell main-
tenance (64), eliminating the common downstream signaling 
mediator SMAD4 did not interfere with normal melanocyte sur-
vival and proliferation. These findings suggest that TGFbRII and 
Smad4 inactivation differentially affect the finely tuned balance of 
combined signaling by BMP and TGF-β ligands in the bulge niche 
(65, 66). Importantly, our data also demonstrate that the inhibi-
tory effect of Smad4-cKO on NrasQ61K-driven hyperpigmentation 
and tumor initiation observed in our mouse melanoma model can-
not simply be due to depletion of the melanocytic lineage. Indeed, 
taking advantage of an inducible system allowing gene manipula-
tion at various stages of tumor progression, we show that Smad4 
is required for proliferation in established skin melanoma. This, 
in turn, reveals the existence of and necessity for proproliferative 
activators of the Smad pathway, such as BMP7, in the context of 
melanoma propagation. Since proproliferative BMP7 appears to 
be dominant over proinvasive factors, the question arises of how 
a metastatic process is induced in melanoma. One possible mech-
anism might involve spatiotemporal changes in the composition 
of the TGF-β superfamily factors to which a tumor cell is exposed, 
where reducing levels of proproliferative factors relative to proin-
vasive factor concentrations would promote the development of 
invasive cells with limited proliferation capacity (8). Whether such 
phenotype switching indeed occurs in vivo remains to be shown. 
Our study offers an alternative, but nonexclusive, mechanism of 
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